Fig. 3
From: Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
PDC/PDX-guided treatment of patients under two independent n = 1 co-clinical trials. a Timeline for patient HN137 from surgery (December), adjuvant chemo-radiation therapy, until tumour recurrence in June. b Graph denoting Log2(IC50) values of HN137-Pri, HN137-Pri cisplatin resistant (CR), HN137-Met, HN137-Met cisplatin resistant (CR) cell lines in the presence of gefitinib. c Computed tomography scan (CT-scan) of recurrent responsive metastatic sites (dermal metastasis (top panel) and lung metastasis (bottom panel)) in HN137 patient, before and after treatment with 250 mg per day of gefitinib. Arrows denote sites of tumours before and after treatment. d Dose response of HN177-PDC to erlotinib and olaparib. Cell viability was determined using CellTiter-Glo reagent. Triplicate data, error bars represent mean ± s.d. e Three independent cohorts of mice (n = 2 for control and n = 3 for treated) bearing HN177-PDX in one flank were treated with vehicle control (Ctrl), 50 mg kg−1 olaparib and 150 mg kg−1 erlotinib. Error bars represent mean ± s.e.m. Two-tail Student’s t test was carried out between olaparib and control group (N.S.: not significant) and between erlotinib and control group **P value <0.01. f Changes in serum carbohydrate antigen 19-9 (CA 19-9) at initial time of diagnosis and during the course of treatment. g CT-scan of recurrent non-responsive lung metastasis in HN137 patient, before and after treatment with 250 mg day−1 of gefitinib. Arrows denote sites of tumours before and after treatment
